The European Commission is working on legal proceedings against AstraZeneca after the drugmaker cut Covid-19 vaccine deliveries to the European Union, sources familiar with the matter said.
The European Commission granted Amarin Corporation Plc’s fish-oil derived heart drug Vazkepa marketing authorization in the European Union, the drugmaker said on March 30.
Swiss drugmakers Roche and Novartis each won European approval for drugs on March 30 in a sign that the rival Basel-based companies are increasingly competing for the same patients.
EU leaders voiced frustration on March 25 over a massive shortfall in contracted deliveries of AstraZeneca Covid-19 vaccines, as a third wave of infections surged across Europe.
The European Union’s drugs regulator on March 11 approved Johnson & Johnson’s single dose Covid-19 vaccine, as the bloc seeks to speed up a stuttering inoculation campaign and boost its supplies.
Johnson & Johnson told the European Union the company is facing supply issues that may complicate plans to deliver 55 million doses of J&J’s Covid-19 vaccine to the bloc in the second quarter of 2021, an EU official told Reuters.
Pfizer slashed in half the volume of Covid-19 vaccines the company will deliver to some EU countries this week, government officials said, as frustration over the U.S. drugmaker’s unexpected cut in supplies grows.
AstraZeneca Plc’s cancer drug Imfinzi was approved in Europe and Britain for a spaced-out regimen in a common type of lung cancer to help reduce the frequency of hospital visits while continuing treatment.
The European Commission approved Swiss drugmaker Roche’s Xofluza to treat influenza in patients aged 12 years and older, the first new influenza antiviral for patients in almost 20 years.
U.S. DoD Awards $1.97 Billion Covid-19 Vaccine Contract to Moderna"Operation Warp Speed" Initiative, AstraZeneca, Canada, Committee for Medicinal Products for Human Use (CHMP), COVID-19 Vaccines, Department of Defense, Emergency Use Authorization, European Commission, Moderna, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Oxford University, United States
The United States Department of Defense (DOD) awarded Moderna a contract valued at $1,966,598,000 for an additional 100 million doses of the company’s Covid-19 vaccine.